inhaled mannitol

Phase 3Small molecule

SSyntara

inhaled mannitol is one of 70 small molecule programs targeting Bronchiectasis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

BronchiectasisActive, not recruiting

Cystic FibrosisActive, not recruiting

BronchiectasisPhase 3

Active, not recruiting

Cystic FibrosisPhase 3

Active, not recruiting

Competition

Competitive Landscape

386 competitors in Cystic Fibrosis

#DrugCompanyPhaseTrials

inhaled mannitol

SSyntara

Phase 3

3 2

Onglyza

AstraZeneca

Preclinical

2 3

Calciferol

Alnylam Pharmaceuticals

Preclinical

1 4

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

3 5

Actimmune

HHorizon Therapeutics Ireland DAC

Preclinical

2 6

Proair HFA

GGlaxo Dba Glaxosmithkline

Preclinical

2 7

Aztreonam Lysine

Gilead

Preclinical

5 8

Capromorelin

UUniversity of Aarhus

Preclinical

1 9

Amitiza

SSucampo Pharma Americas, LLC

Preclinical

1 10

Advil

KKenvue Brands

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cystic Fibrosis3 trials

Long Term Administration of Inhaled Mannitol in Cystic Fibrosis

Completed·SSyntara·Phase 3·NCT00630812·318 enrolled

A Phase 2 Study to Determine the Safety and Efficacy of Inhaled Dry Powder Mannitol in Cystic Fibrosis

Completed·SSyntara·Phase 2·NCT00455130

A Safety and Efficacy Trial of Inhaled Mannitol in Adult Cystic Fibrosis Subjects

Completed·SSyntara·Phase 3·NCT02134353·423 enrolled

Bronchiectasis1 trial

Inhaled Mannitol as a Mucoactive Therapy for Bronchiectasis

Completed·SSyntara·Phase 3·NCT00669331·485 enrolled

Efficacy1 trial

Crossover Trial Determining the Efficacy of Dry Powder Mannitol to Improve Lung Function in Subjects Aged 6-17 Years

Completed·SSyntara·Phase 2·NCT01883531·95 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for inhaled mannitol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — inhaled mannitol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for inhaled mannitol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Syntara company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSyntara

inhaled mannitol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cystic Fibrosis3 trials

Bronchiectasis1 trial

Efficacy1 trial

References

Drug Info

Quick Facts

Related News